CO2019009216A2 - Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas - Google Patents

Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas

Info

Publication number
CO2019009216A2
CO2019009216A2 CONC2019/0009216A CO2019009216A CO2019009216A2 CO 2019009216 A2 CO2019009216 A2 CO 2019009216A2 CO 2019009216 A CO2019009216 A CO 2019009216A CO 2019009216 A2 CO2019009216 A2 CO 2019009216A2
Authority
CO
Colombia
Prior art keywords
colistin
association
acetylcysteine
bacterial infections
respiratory tract
Prior art date
Application number
CONC2019/0009216A
Other languages
English (en)
Inventor
Gian Maria Rossolini
Lucia Pallecchi
Francesco Sergio
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of CO2019009216A2 publication Critical patent/CO2019009216A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN La presente invención hace referencia a una asociación farmacológica sinérgica de NAC y colistina para su uso en el tratamiento de una infección bacteriana causada por uno o más patógenos seleccionados de cepas de S. maltophilia y A. baumannii, en particular una infección bacteriana asociada con una enfermedad del tracto respiratorio, como una enfermedad crónica del tracto respiratorio que comprende FQ, bronquiectasias sin FQ y EPOC.
CONC2019/0009216A 2017-02-27 2019-08-27 Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas CO2019009216A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17158241.4A EP3366284A1 (en) 2017-02-27 2017-02-27 Association of n-acetylcysteine and colistin for use in bacterial infections
PCT/EP2018/054611 WO2018154091A1 (en) 2017-02-27 2018-02-26 Association of n-acetylcysteine and colistin for use in bacterial infections

Publications (1)

Publication Number Publication Date
CO2019009216A2 true CO2019009216A2 (es) 2020-01-17

Family

ID=58191354

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0009216A CO2019009216A2 (es) 2017-02-27 2019-08-27 Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas

Country Status (10)

Country Link
US (2) US11382948B2 (es)
EP (2) EP3366284A1 (es)
JP (1) JP7241687B2 (es)
CN (1) CN110352053B (es)
AU (1) AU2018223985B2 (es)
BR (1) BR112019017113A2 (es)
CA (1) CA3053441A1 (es)
CO (1) CO2019009216A2 (es)
EA (1) EA201991889A1 (es)
WO (1) WO2018154091A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000023665A1 (it) 2020-10-07 2022-04-07 Brenta S R L Sistema di nanoparticelle per il veicolo e la somministrazione di principi attivi e relativo metodo di produzione, nonché attività di eradicazione di biofilm
EP4282410A1 (en) 2022-05-27 2023-11-29 Zambon S.p.A. Association of colistin and n-acetalcysteine in the treatment of bacterial infections by p. aeruginosa in a mature biofilm phase of growth

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69705414T2 (de) * 1996-11-15 2002-05-02 Pathogenesis Corp., Seattle Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
JP7241687B2 (ja) 2023-03-17
US20220370549A1 (en) 2022-11-24
EP3585372A1 (en) 2020-01-01
AU2018223985B2 (en) 2023-11-23
EA201991889A1 (ru) 2020-01-09
EP3366284A1 (en) 2018-08-29
CN110352053A (zh) 2019-10-18
CA3053441A1 (en) 2018-08-30
US11382948B2 (en) 2022-07-12
US12102660B2 (en) 2024-10-01
US20210128678A1 (en) 2021-05-06
AU2018223985A1 (en) 2019-08-29
WO2018154091A1 (en) 2018-08-30
BR112019017113A2 (pt) 2020-04-07
CN110352053B (zh) 2023-03-28
JP2020508318A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
BR112016017690A2 (pt) Tratamentos para acne resistente
CL2016002971A1 (es) Combinación.
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
GT201500081A (es) Derivados de exendina-4 como agonistas duales de glp1/glucagón
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112015028385A2 (pt) composição compreendendo bactérias de ácido láctico para uso no tratamento preventivo e/ou curativo da vaginose bacteriana
CL2017002176A1 (es) Identificación bacteriana y prueba de susceptibilidad antimicrobiana.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
EA201591761A1 (ru) Композиции на основе наночастиц
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
AR101740A1 (es) Terapia de combinación y composiciones
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
CO2021014694A2 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
CO2019009216A2 (es) Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas